
|Articles|October 1, 2003
GALDERMA ACHIEVES FDA APPROVAL
Galderma Laboratories has received FDA approval for Clobex (clobetasol propionate 0.05 percent) in a lotion formulation. The class I steroid prescription lotion is designed to control and treat steroid-responsive dermatoses, including moderate-to-severe psoriasis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Phase 2 Nemolizumab Trial Opens for CPUO
5


















